德国MorphoSys AG
MorphoSys AG是一家上市生物技术企业， 位于慕尼黑Martinsried 区， 其业务是专门开发人体完全抗体， 发现治疗危害生命疾病的新切入点， 开发治疗这些疾病的以抗体为基础的创新性药品。 MorphoSys的目标是， 把自己的HuCAL抗体数据库发展成研究和诊断以及药品开发用新一代抗体的世界标准。 该企业和大多数知名制药公司进行合作和共同研究， 其中有Boehringer Ingelheim、 Centocor/Johnson & Johnson、 Novartis、 Pfizer和Roche等。 在这些伙伴关系的框架中， MorphoSys跟踪了50多个活性治疗抗体项目。 该企业通过独有的许可证和阶段性结果付款以及根据所有产品销售额所付的产品税享受这些开发成绩。 除此之外， MorphoSys通过业务单元AbD Serotec在研究 用抗体市场上开展业务。 AbD Serotec在德国(慕尼黑)、 美国(北 卡罗来 纳州Raleigh)和英国(牛津)设有子公司。

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

The Company, founded in 1992, possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises several billion different, fully human antibodies. HuCAL is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet predefined specifications.

Presently, MorphoSys prosecutes its business in two operating segments. One segment, the Therapeutic Antibodies unit, develops drug candidates for commercial partners as well as MorphoSys's own proprietary product pipeline. In this regard, the Company has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies and also generated several proprietary therapeutic antibody candidates for out-licensing to partners. MorphoSys's second operating segment, the Research Antibodies unit, delivers high-quality antibodies to the research market, under the brand AbD Serotec. Two successful acquisitions of U.S. and U.K.-based antibody suppliers have significantly strengthened and broadened MorphoSys’s position in the research antibody market. The resulting combined activities of MorphoSys’s AbD unit serve all segments of the research and diagnostics markets.